New drug teclistamab tested for safety in Tough-to-Treat blood cancer

NCT ID NCT07030517

Ongoing Disease control Sponsor: Johnson & Johnson Private Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study tests the safety of teclistamab, a drug given as a shot, in 75 Indian adults with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see how safe it is in routine practice. Participants must have tried specific prior therapies and have worsening disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab (a drug given as a shot under the skin)
What this could lead to: If successful, this could confirm that teclistamab is a safe option for Indian patients with hard-to-treat multiple myeloma, potentially offering a new treatment choice.
What could go wrong: This is a small, early-stage safety study (75 participants) in a specific population, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

All India Institute of Medical Sciences

New Delhi, 110029, India
Bhagwan Mahaveer Cancer Hospital & Research Centre

Jaipur, 302017, India
Christian Medical College

Ratnagiri Kilminnal, 632517, India
Jawaharlal Institute of Postgraduate Medical Education and Research

Puducherry, 605006, India
KIMS-Kingsway Hospitals

Nagpur, 440001, India
M S Ramaiah Medical College and Hospital

Bangalore, 560054, India
Post Graduate Institute of Medical Education And Research PGIMER

Chandigarh, 160012, India
Rajiv Gandhi Cancer Institute & Research Centre

New Delhi, 110085, India
Regional Cancer Centre

Thiruvananthapuram, 695011, India
St. Johns Medical College And Hospital

Bengaluru, 560034, India
Tata Medical Center

Kolkata, 700156, India
Tata Memorial Hospital

Mumbai, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.